Drugs / Rehydragel®
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04826094 Background | Mar 2021 → Feb 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rehydragel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04826094 ↗ |
| Modality | Other / unclassified | “Adjuvant.” NCT04826094 ↗ |
| Route | Intramuscular | “Administered by intramuscular injection.” NCT04826094 ↗ |